摘要
目的探讨雾化吸入重组人干扰素α2b注射液治疗小儿喘息性支气管炎的有效性及安全性。方法80例小儿喘息性支气管炎患儿,以随机数字表法分为对照组和观察组,每组40例。对照组接受常规对症治疗,观察组在对照组基础上加用重组人干扰素α2b注射液雾化吸入治疗。比较两组临床疗效、治疗后症状缓解时间、治疗前后炎性因子水平及不良反应发生率。结果观察组治疗总有效率95.00%高于对照组的80.00%,差异有统计学意义(P<0.05)。观察组治疗后咳嗽、咯痰、气喘、发热缓解时间分别为(2.86±0.54)、(1.21±0.20)、(2.55±0.50)、(1.85±0.30)d,均明显短于对照组的(4.12±0.85)、(2.02±0.56)、(3.85±0.62)、(2.95±0.32)d,差异有统计学意义(P<0.05)。治疗7 d后,观察组白细胞计数(WBC)、外周血中嗜酸性粒细胞直接计数(EOS)与白细胞介素-4(IL-4)水平分别为(7.22±1.06)×10^(9)/L、(0.36±0.10)×10^(9)/L、(2.00±0.64)ng/ml,均明显低于对照组的(10.05±1.82)×10^(9)/L、(0.75±0.20)×10^(9)/L、(4.35±1.00)ng/ml,差异有统计学意义(P<0.05)。两组不良反应发生率比较差异无统计学意义(P>0.05)。结论雾化吸入重组人干扰素α2b注射液可提升小儿喘息性支气管炎的治疗效果,加快疾病症状缓解,降低机体炎性因子水平,且不良反应少。
Objective To discuss the effectiveness and safety of aerosol inhalation of recombinant human interferonα2b injection in the treatment of asthmatic bronchitis in children.Methods A total of 80 children with asthmatic bronchitis were divided into control group and observation group according to the random numerical table,with 40 cases in each group.The control group received conventional symptomatic treatment,and the observation group was additionally treated with aerosol inhalation of recombinant human interferonα2b injection.The clinical efficacy,symptom remission time,inflammatory factors before and after treatment,and the incidence of adverse reactions were compared between the two groups.Results The total effective rate of 95.00%in the observation group was higher than that of 80.00%in the control group,and the difference was statistically significant(P<0.05).After treatment,the remission time of cough,sputum,asthma and fever were(2.86±0.54),(1.21±0.20),(2.55±0.50)and(1.85±0.30)d in the observation group,which were significantly shorter than those of(4.12±0.85),(2.02±0.56),(3.85±0.62)and(2.95±0.32)d in the control group,and the differences were statistically significant(P<0.05).After 7 d of treatment,the levels of white blood cell count(WBC),eosinophils(EOS)and interleukin-4(IL-4)in peripheral blood were(7.22±1.06)×10^(9)/L,(0.36±0.10)×10^(9)/L and(2.00±0.64)ng/ml in the observation group,which were significantly lower than those of(10.05±1.82)×10^(9)/L,(0.75±0.20)×10^(9)/L and(4.35±1.00)ng/ml in the control group,and the differences were statistically significant(P<0.05).There was no statistically significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion Aerosol inhalation of recombinant human interferonα2b injection can improve the therapeutic effect of asthmatic bronchitis in children,accelerate the remission of disease symptoms,reduce the level of inflammatory factors with few adverse reactions.
作者
孙志伟
姜舒亚
张海英
SUN Zhi-wei;JIANG Shu-ya;ZHANG Hai-ying(Pediatric Department,904th Hospital of the Joint Logistics Support Force of the Chinese People's Liberation Army,Wuxi 224200,China)
出处
《中国现代药物应用》
2023年第14期100-103,共4页
Chinese Journal of Modern Drug Application
关键词
小儿喘息性支气管炎
重组人干扰素α2b注射液
雾化吸入
炎性因子
不良反应
Asthmatic bronchitis in children
Recombinant human interferonα2b injection
Aerosol inhalation
Inflammatory factors
Adverse reactions
